Authors: Koshkina, N. V.; Waldrep, J. C.; Knight, V.

Source: Current Cancer Drug Targets, Volume 3, Number 4, August 2003 , pp. 251-264(14)

Publisher: Bentham Science Publishers

Abstract:

Lung cancer is the largest and the most common cause of cancer-related deaths worldwide. The cure rate for lung cancer remains lowest among all malignancies. The discovery of new chemical agents with activity in first onset and recurrent disease is crucial for advancing treatment of patients with pulmonary tumors. Camptothecins are known as inhibitors of topoisomerase I, one of the key enzymes for DNA replication and subsequent cell proliferation. Preclinical and clinical studies had shown that the camptothecins are active against lung cancer and other solid malignancies. In this paper, we review the status of camptothecin and derivatives for treatment of pulmonary cancers, including the development of new formulations and, particularly, novel aerosol routes of drug administration, and their application in combination therapy.

Keywords: camptothecins; aerosol; lung cancer; cancer-related deaths; malignancies

Document Type: Review article

DOI: http://dx.doi.org/10.2174/1568009033481930

Affiliations: 1: Division Pediatrics, MD Anderson Cancer Center, 1515 Holcombe Blvd., TX 77030, Houston.

Publication date: 2003-08-01

More about this publication?

• Current Cancer Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular drug targets involved in cancer, e.g. disease specific proteins, receptors, enzymes, genes.
  Each issue of the journal contains a series of timely in-depth reviews written by leaders in the field covering a range of current topics on drug targets involved in cancer.
  As the discovery, identification, characterization and validation of novel human drug targets for anti-cancer drug discovery continues to grow; this journal has become essential reading for all pharmaceutical scientists involved in drug discovery and development.

Related content

• In this: publication
• By this: publisher
• In this Subject: Oncology ,  Pharmacology
• By this author: Koshkina, N. V. ;  Waldrep, J. C. ;  Knight, V.

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers